glp-1 receptor agonists and sglt2 inhibitors SGLT-2 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease How Do SGLT2 (Sodium-Glucose Cotransporter

In clinical trials, GLP-1 RAs were shown to significantly lower blood pressure (BP) in addition to HbA1c and body weight (BW), indicating the possibility as anti-hypertensive medication of type 2 DM individuals

The best results happen when the medicine is used along with healthy eating and exercise, and people may gain weight back if they stop taking the medicine

Compounding pharmacies and investors have brought legal challenges to enjoin the FDA from enforcing the changes to the shortage list, but have so far been unsuccessful

From a scientific breakthrough studying the oft fasting Gila Monster has become the current successful weight loss therapies, here's how.

As fatty liver disease continues to drive downstream costs, this signal is getting serious attention

Current expectations point to FDA review and potential approval in the 2027 to 2028 range